All In Biotech

Drug Trial Radar · NCT01904604

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Sep 2013

Primary completion

Aug 2015

Study completion Aug 21, 2018

Sponsor

Sponsor type
NIH
Collaborators
Consortium of Food Allergy Research
First posted
Jul 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.

Conditions

  • Peanut Hypersensitivity
  • Food Hypersensitivity
  • Hypersensitivity
  • Hypersensitivity, Immediate

Interventions

  • Placebo Viaskin® PatchBiological

    Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.

  • Low-dose DBV712 Viaskin® PatchBiological

    100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.

  • High-dose DBV712 Viaskin® PatchBiological

    250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With a Successful Treatment ResponseTime frame: Week 52

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • National Jewish Health

    Denver, Colorado

  • The Johns Hopkins University

    Baltimore, Maryland

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University of North Carolina at Chapel Hill School of Medicine

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.